YOU ARE HERE: LAT HomeCollections

The Nation

FDA Advisors OK Disputed Pain Relievers

Medical experts acknowledge that the drugs, including Vioxx and Celebrex, pose dangers. They call for stronger warnings.

February 19, 2005|Ricardo Alonso-Zaldivar and Denise Gellene | Times Staff Writers

WASHINGTON — A Food and Drug Administration advisory panel voted Friday to let doctors prescribe Cox-2 painkillers, including Celebrex and Vioxx, but recommended stronger warnings about the risk of heart attacks and strokes.

Doctors, scientists and other experts on the 32-member panel overwhelmingly agreed that Cox-2 inhibitors -- hailed as a breakthrough in treating severe arthritis pain when they first won FDA approval -- all significantly increased the risk of cardiovascular problems in patients.

The panel proposed that Celebrex, Vioxx and Bextra, the third Cox-2 drug cleared by the FDA, carry "black box" warnings -- the strongest admonishment the FDA can give to doctors. Such warnings are likely to discourage use of the drugs.

The panel's decisions, made during three days of hearings and deliberations, sought to balance the health risks against the benefits the drugs provide to tens of millions who take them. In what amounted to a series of split verdicts, panel members divided over the risks posed by individual drugs in the Cox-2 inhibitor group.

In the case of Vioxx -- which was taken off the market voluntarily last fall by its maker, Merck, after a company-sponsored study confirmed the dangers -- panel members voted to approve its use by a margin of two votes.

The FDA, which has pledged prompt regulatory action on the panel recommendations, likely will have to tailor different responses to each of the three drugs. The agency typically follows its panels' recommendations.

Beyond the effect of its decisions on patients and on billions of dollars in revenues for drug makers, the blue-ribbon panel was widely seen as a test of the FDA's readiness to deal with problems that had embroiled the agency in controversy for more than a year.

Comprised of two FDA advisory committees, the panel was convened in response to evidence of weaknesses in the FDA's system for monitoring the safety of drugs after it had approved them for market.

In particular, critics had charged, the FDA was too slow and too dependent on self-reporting by manufacturers when it came to problems that emerged once huge numbers of people began using the drugs.

A leading FDA congressional critic, Sen. Charles E. Grassley (R-Iowa) said Friday: "The joint advisory committee meetings this week were valuable for their transparency and respect for the scientific process."

But "I remain troubled by the FDA's reluctance to be fully transparent and prioritize issues of drug safety," Grassley said. He has complained that the agency does not give sufficient resources to monitoring the safety of drugs already on the market, and he has charged that it has tried to muffle internal critics.

The Cox-2 inhibitors -- which have been taken by about 50 million people worldwide -- presented the FDA with a particularly difficult dilemma.

On the one hand, the drugs offered benefits that many doctors and patients considered vital; there also were indications that the painkillers might have value in treating other diseases, including colon cancer. On the other hand, there was strong evidence of cardiovascular risks.

The panel's effort to balance risks and benefits was evident in members' comments:

"Clearly someone who is leading a poor quality of life [due to pain] and understands the risks is a good candidate [for Celebrex]," said Dr. Michael Domanski of the National Institutes of Health. "I don't think we should take this pill out of the hands of doctors."

Said Dr. Steven Shafer of Stanford University: "I voted last night when my father, an 89-year-old man with no cardiac risk factors, asked me if he should continue his Celebrex.

"I said yes."

For Vioxx, the committee's vote could mean a new lease on life. Merck said in a statement that the company looked forward to discussions with the FDA.

Celebrex and Bextra, which have remained on the market during the safety controversy, are produced by Pfizer. Joseph Feczko, Pfizer's president of worldwide development, told Bloomberg news service Friday that the decisions gave the company "some more clarity about how the experts thought of these drugs and steps to go forward."

Committee members were nearly unanimous in recommending that Celebrex remain available. The votes on Vioxx and Bextra were much closer. On Vioxx, 17 members voted to keep the drug, 15 to ban it. On Bextra, 17 voted to keep it, 13 to ban it, and two abstained.

As for traditional painkillers known as nonsteroidal anti-inflammatory drugs, or NSAIDs, the committee recommended that labels be changed to caution that the long-term heart risks were not known. However, the committee largely absolved naproxen -- the active ingredient in Aleve -- a drug whose safety has been questioned.

Many panel members said the FDA should narrow the pool of patients who can receive Celebrex, and also limit the doses that can be prescribed.

Following the panel's decisions, Pfizer shares rose $1.74 to $26.80, and Merck's shares gained $3.76 to $32.61 -- both on the New York Stock Exchange.

Los Angeles Times Articles